| Literature DB >> 16971093 |
Hatem Kallel1, Mabrouk Bahloul, Leila Hergafi, Malek Akrout, Wajdi Ketata, Hedi Chelly, Chokri Ben Hamida, Noureddine Rekik, Adnane Hammami, Mounir Bouaziz.
Abstract
The objective of this study was to determine the efficacy of systemic colistin therapy in the treatment of nosocomial infections caused by multidrug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa and to study related adverse events. We prospectively studied 78 infections caused by multidrug-resistant A. baumannii or P. aeruginosa that were treated with colistin. The sites of infection were pulmonary infection (78.2%), urinary tract infection (7.7%), primary bloodstream infection (11.5%) and meningitis (2.6%). The mean daily dose of colistin was 5.5+/-1.1 MU/day (range 2-9 MU/day) and the mean duration of colistin therapy was 9.3+/-3.8 days (range 5-21 days). A favourable clinical response to colistin occurred in 60 cases (76.9%). Renal failure occurred in only seven cases. We conclude that colistin can be a safe and effective salvage therapeutic option for nosocomial infections caused by multidrug-resistant A. baumannii or P. aeruginosa.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16971093 DOI： 10.1016/j.ijantimicag.2006.07.008
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN： 0924-8579 Impact factor: 5.283